ABIONYX Pharma SA (FRA:609)

Market Cap	97.94M +120.3%
Revenue (ttm)	4.06M -10.7%
Net Income	-5.55M
EPS	-0.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.710
Previous Close	2.765
Day's Range	2.710 - 2.710
52-Week Range	1.126 - 5.000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 24, 2026

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 49
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 609

Financial Performance

In 2025, ABIONYX Pharma's revenue was 4.06 million, a decrease of -10.72% compared to the previous year's 4.55 million. Losses were -5.55 million, 26.7% more than in 2024.